hatte nochmal kurzen Kontakt zur Amy... nicht wirklich was neues aber ich denke die Anker Aktionäre deuten ihre Unterstützung an...
Dear Daniel,
Most institutional investors are looking at the big picture -- the long-term opportunity that we expect to address with Amphora in contraception and STI prevention, and our BV vaginal gel as well, assuming positive clinical and regulatory outcomes. We expect to report Phase 3 contraception data in Q1 2019 with an FDA decision by the end of next year and launch shortly thereafter, all of which are expected to build value.
Finally, to your prior email, the S-3 you refer to was to register their legacy shares to enable them to sell if they should care to. It was not indicating that they intend to do so. And as you noted I'm sure in Friday's S-1 filing, current institutional shareholders may participate in the planned offering for up to $10 million, which statement is a show of their ongoing support.
Regards,
Amy |